Evidentic

Executive Summary

Evidentic is a German biotech services company headquartered in Berlin that accelerates early-stage drug development by supplying small, clinical-grade aliquots of licensed therapeutic molecules. Operating as a licensed pharmaceutical wholesaler, the company sources FDA/EMA-approved medicines, precisely divides them under sterile conditions, and stores them for on-demand shipment to R&D teams. This model provides researchers with fast, cost-efficient access to reference products essential for characterization, comparability, and analytical studies, eliminating the need to purchase entire vials of expensive biologics. By reducing costs and streamlining access to high-quality reference material, Evidentic addresses a critical bottleneck in the drug development pipeline. The company's service model is particularly valuable in the growing biologics market, where analytical comparability studies are increasingly required for biosimilar development and quality control. Evidentic's established network as a wholesaler and its sterile aliquot capabilities position it well to capture demand from both small biotechs and large pharmaceutical companies. As the regulatory landscape emphasizes the importance of reference standards, Evidentic's offerings are likely to see sustained demand. Future growth may come from expanding its product catalog to include newly approved therapies, entering new geographic markets, or forming strategic partnerships with drug manufacturers.

Upcoming Catalysts (preview)

• H2 2026Expansion of product catalog to include recently approved biologics80% success
• TBDStrategic partnership with a top pharmaceutical company for reference standard supply65% success
• Q1 2027FDA/EMA certification for additional sterile manufacturing capacity70% success